Radiprodil

Radiprodil
Clinical data
Other namesRGH-896; RGH896
Routes of
administration		Oral
Drug classNR2B subunit-containing NMDA receptor negative allosteric modulator
Identifiers
  • 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H20FN3O4
Molar mass397.406 g·mol−1
3D model (JSmol)
  • C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4
  • InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)
  • Key:GKGRZLGAQZPEHO-UHFFFAOYSA-N

Radiprodil (INNTooltip International Nonproprietary Name; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. It is taken orally. The drug is being developed by GRIN Therapeutics. As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. The drug was first described in the scientific literature by 2003.

See also

References

  1. 1 2 3 4 5 "GRIN Therapeutics". AdisInsight. 28 December 2025. Retrieved 16 January 2026.
  2. ↑ Auvin S, Dozières-Puyravel B, Avbersek A, Sciberras D, Collier J, Leclercq K, et al. (March 2020). "Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome". Annals of Clinical and Translational Neurology. 7 (3): 343–352. doi:10.1002/acn3.50998. PMC 7085998. PMID 32106360.
  3. ↑ Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, et al. (September 2017). "GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors". Neuropharmacology. 123: 322–331. doi:10.1016/j.neuropharm.2017.05.017. PMID 28533163.
  4. ↑ Farkas S, Horvath C, Nagy J (2003). RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Society for Neuroscience. Washington, DC. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner.